
Precision BioSciences, Inc.: shareholders and insiders
Price
$7.53
November 20, 2026Market cap $210M
What Ploutos Investor adds for Precision BioSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
$63.2K
3 people
Sold on the market
$458.8K
4 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $29.5K by 3 people·sold $458.8K by 4 people
- 2025: bought $33.7K by 3 people, no sales
- 2026: bought $29.5K by 3 people, sold $458.8K by 4 people
- Nov 10, 2026Dario ScimecaChief Legal OfficerKind10b5-1
- Sep 28, 2026Stanley FrankelDirectorKind
- Sep 25, 2026Melinda BrownDirectorKind
- Sep 25, 2026Geno J GermanoDirectorKind
- Feb 18, 2026J. Jefferson SmithChief Research OfficerKind10b5-1
- Feb 18, 2026Dario ScimecaGeneral Counsel and SecretaryKind10b5-1
- Feb 18, 2026John Alexander KellyChief Financial OfficerKind10b5-1
- Feb 18, 2026Michael AmorosoPresident and CEOKind10b5-1
- Jan 22, 2026Michael AmorosoPresident and CEOKind10b5-1
- Jan 21, 2026J. Jefferson SmithChief Research OfficerKind10b5-1
- Jan 21, 2026John Alexander KellyChief Financial OfficerKind10b5-1
- Jan 21, 2026Dario ScimecaGeneral Counsel and SecretaryKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Dario ScimecaChief Legal Officer | 10b5-1 | 2,821 | $9.75 | $27.5K | Form 4 |
| Sep 28, 2026 | Stanley FrankelDirector | 1,000 | $6.00 | $6.0K | Form 4 | |
| Sep 25, 2026 | Melinda BrownDirector | 1,135 | $6.27 | $7.1K | Form 4 | |
| Sep 25, 2026 | Geno J GermanoDirector | 2,609 | $6.28 | $16.4K | Form 4 | |
| Feb 18, 2026 | J. Jefferson SmithChief Research Officer | 10b5-1 | 4,925 | $3.84 | $18.9K | Form 4 |
| Feb 18, 2026 | Dario ScimecaGeneral Counsel and Secretary | 10b5-1 | 4,925 | $3.84 | $18.9K | Form 4 |
| Feb 18, 2026 | John Alexander KellyChief Financial Officer | 10b5-1 | 8,149 | $3.84 | $31.3K | Form 4 |
| Feb 18, 2026 | Michael AmorosoPresident and CEO | 10b5-1 | 20.6K | $3.84 | $78.9K | Form 4 |
| Jan 22, 2026 | Michael AmorosoPresident and CEO | 10b5-1 | 34.8K | $4.17 | $145.1K | Form 4 |
| Jan 21, 2026 | J. Jefferson SmithChief Research Officer | 10b5-1 | 10.2K | $4.03 | $41.1K | Form 4 |
| Jan 21, 2026 | John Alexander KellyChief Financial Officer | 10b5-1 | 15.2K | $4.03 | $61.3K | Form 4 |
| Jan 21, 2026 | Dario ScimecaGeneral Counsel and Secretary | 10b5-1 | 8,854 | $4.03 | $35.7K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by DTIL's officers and directors from 2019 up to November 19, 2025, 7 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 2 more, back to 2019
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Readout Capital, LPwith 4 more personsShare of class9.40%
- Aberdeen Group plcwith 1 more personShare of class8.88%
- Bleichroeder LPwith 2 more personsCommon SharesShare of class8.21%
- Octagon Capital Advisors LPwith 2 more personsShare of class5.73%
- Lynx1 Capital Management LPwith 1 more personShare of class5.40%
- BlackRock, Inc.Share of class5.01%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Readout Capital, LPwith 4 more persons | 9.40% | 1.12M | Aug 14, 20252 filings since Mar 26, 2025 | 13G/A | |
| Aberdeen Group plcwith 1 more person | 8.88% | 2.14M | Jan 27, 2026 | 13G | |
| Bleichroeder LPwith 2 more personsCommon Shares | 8.21% | 1.90M | Feb 13, 20262 filings since Aug 14, 2025 | 13G/A | |
| Octagon Capital Advisors LPwith 2 more persons | 5.73% | 1.65M | Nov 3, 20262 filings since Feb 10, 2026 | 13G/A | |
| Lynx1 Capital Management LPwith 1 more person | 5.40% | 1.39M | Jul 20, 20264 filings since Feb 14, 2025 | 13G | |
| BlackRock, Inc. | 5.01% | 1.38M | Oct 27, 2026 | 13G |
Fell to 5% or less (7)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Weinstein Benjamin4.00%Aug 24, 202613G/A
- Empery Asset Management, LP4.99%Jul 29, 202613G/A
- Tang Capital Management0.00%Feb 17, 202613G/A
- Novartis Pharma AG3.70%Aug 6, 202513G/A
- Aquilo Capital, L.P.0.00%Aug 6, 202513G/A
- Highbridge Capital Management, LLC3.70%Apr 25, 202513G/A
- Janus Henderson Group0.00%Feb 14, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter+122%
- Citadel Advisors (Griffin)In the quarter-12%
- Renaissance TechnologiesIn the quarter+11%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 31.3K | +122% | $200.0K | 0.00% |
| Citadel Advisors (Griffin) | 60.6K | -12% | $400.0K | 0.00% |
| Renaissance Technologies | 76.3K | +11% | $500.0K | 0.00% |
| AQR Capital | 67.5K | $400.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.44% of its shares outstanding were held short, -6.3% since the report before.
- Shares held short
- 2.36M
- 8.44%
- Since the report before2.51M on Sep 30, 2026
- -6.3%
- 9.4
- 251.9K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 89%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 606.9K
- Nov 15, 2023: Shares held short 852.5K
- Nov 30, 2023: Shares held short 372.5K
- Dec 15, 2023: Shares held short 371.2K
- Dec 29, 2023: Shares held short 385.2K
- Jan 12, 2024: Shares held short 2.15M
- Jan 31, 2024: Shares held short 1.65M
- Feb 15, 2024: Shares held short 39.8K
- Feb 29, 2024: Shares held short 48.6K
- Mar 15, 2024: Shares held short 178.0K
- Mar 28, 2024: Shares held short 288.9K
- Apr 15, 2024: Shares held short 349.7K
- Apr 30, 2024: Shares held short 336.0K
- May 15, 2024: Shares held short 344.1K
- May 31, 2024: Shares held short 344.8K
- Jun 14, 2024: Shares held short 306.7K
- Jun 28, 2024: Shares held short 296.9K
- Jul 15, 2024: Shares held short 275.8K
- Jul 31, 2024: Shares held short 251.6K
- Aug 15, 2024: Shares held short 255.2K
- Aug 30, 2024: Shares held short 234.8K
- Sep 13, 2024: Shares held short 234.3K
- Sep 30, 2024: Shares held short 217.6K
- Oct 15, 2024: Shares held short 214.5K
- Oct 31, 2024: Shares held short 214.5K
- Nov 15, 2024: Shares held short 239.9K
- Nov 29, 2024: Shares held short 269.5K
- Dec 13, 2024: Shares held short 274.5K
- Dec 31, 2024: Shares held short 306.7K
- Jan 15, 2025: Shares held short 912.1K
- Jan 31, 2025: Shares held short 756.6K
- Feb 14, 2025: Shares held short 774.9K
- Feb 28, 2025: Shares held short 736.6K
- Mar 14, 2025: Shares held short 618.3K
- Mar 31, 2025: Shares held short 752.7K
- Apr 15, 2025: Shares held short 652.2K
- Apr 30, 2025: Shares held short 666.8K
- May 15, 2025: Shares held short 646.4K
- May 30, 2025: Shares held short 571.0K
- Jun 13, 2025: Shares held short 545.7K
- Jun 30, 2025: Shares held short 1.30M
- Jul 15, 2025: Shares held short 1.08M
- Jul 31, 2025: Shares held short 1.27M
- Aug 15, 2025: Shares held short 1.22M
- Aug 29, 2025: Shares held short 1.14M
- Sep 15, 2025: Shares held short 1.16M
- Sep 30, 2025: Shares held short 1.14M
- Oct 15, 2025: Shares held short 464.0K
- Oct 31, 2025: Shares held short 486.0K
- Nov 14, 2025: Shares held short 532.9K
- Nov 28, 2025: Shares held short 636.7K
- Dec 15, 2025: Shares held short 811.4K
- Dec 31, 2025: Shares held short 1.11M
- Jan 15, 2026: Shares held short 1.32M
- Jan 30, 2026: Shares held short 1.38M
- Feb 13, 2026: Shares held short 1.48M
- Feb 27, 2026: Shares held short 1.38M
- Mar 13, 2026: Shares held short 1.40M
- Mar 31, 2026: Shares held short 1.17M
- Apr 15, 2026: Shares held short 1.25M
- Apr 30, 2026: Shares held short 1.41M
- May 15, 2026: Shares held short 1.51M
- May 29, 2026: Shares held short 1.67M
- Jun 15, 2026: Shares held short 1.94M
- Jun 30, 2026: Shares held short 2.30M
- Jul 15, 2026: Shares held short 2.38M
- Jul 31, 2026: Shares held short 2.88M
- Aug 14, 2026: Shares held short 2.40M
- Aug 31, 2026: Shares held short 2.52M
- Sep 15, 2026: Shares held short 2.22M
- Sep 30, 2026: Shares held short 2.51M
- Oct 15, 2026: Shares held short 2.36M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading55.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 55.0% of the shares in the reported trades were short sales, against 49.5% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 55.0%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 49.5%
- Change
- +5.5 pts
- Short sales a dayon average, of 247.8K shares
- 136.4K
- More than atof 3,666 US-listed companies, same days
- 67%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 62.8%
- Oct 14, 2026: Short sales 46.3%
- Oct 15, 2026: Short sales 45.2%
- Oct 16, 2026: Short sales 20.5%
- Oct 19, 2026: Short sales 53.9%
- Oct 20, 2026: Short sales 42.9%
- Oct 21, 2026: Short sales 60.1%
- Oct 22, 2026: Short sales 65.4%
- Oct 23, 2026: Short sales 64.6%
- Oct 26, 2026: Short sales 43.2%
- Oct 27, 2026: Short sales 57.2%
- Oct 28, 2026: Short sales 52.3%
- Oct 29, 2026: Short sales 53.7%
- Oct 30, 2026: Short sales 56.5%
- Nov 2, 2026: Short sales 69.3%
- Nov 3, 2026: Short sales 45.2%
- Nov 4, 2026: Short sales 64%
- Nov 5, 2026: Short sales 50.2%
- Nov 6, 2026: Short sales 52.1%
- Nov 9, 2026: Short sales 38%
- Nov 10, 2026: Short sales 55.7%
- Nov 11, 2026: Short sales 37.7%
- Nov 12, 2026: Short sales 66.8%
- Nov 13, 2026: Short sales 78.1%
- Nov 16, 2026: Short sales 75.6%
- Nov 17, 2026: Short sales 64.5%
- Nov 18, 2026: Short sales 73.7%
- Nov 19, 2026: Short sales 77.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Michael AmorosoPresident and CEODirectly243.4K
- John Alexander KellyChief Financial OfficerDirectly125.9K
- J. Jefferson SmithChief Research OfficerDirectly121.9K
- Dario ScimecaGeneral Counsel and SecretaryDirectly56.8K
- Geno J GermanoDirectorDirectly47.5K
- Melinda BrownDirectorDirectly45.5K
- Stanley FrankelDirectorDirectly41.5K
- Kevin BuehlerDirectorDirectly28.1K
- Alan ListChief Medical OfficerDirectly4,488
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Michael AmorosoPresident and CEO | 243.4K | – | Feb 18, 2026 | Form 4 |
| John Alexander KellyChief Financial Officer | 125.9K | – | Feb 18, 2026 | Form 4 |
| J. Jefferson SmithChief Research Officer | 121.9K | – | Feb 18, 2026 | Form 4 |
| Dario ScimecaGeneral Counsel and Secretary | 56.8K | – | Nov 10, 2026 | Form 4 |
| Geno J GermanoDirector | 47.5K | – | Sep 25, 2026 | Form 4 |
| Melinda BrownDirector | 45.5K | – | Sep 25, 2026 | Form 4 |
| Stanley FrankelDirector | 41.5K | – | Sep 28, 2026 | Form 4 |
| Kevin BuehlerDirector | 28.1K | – | Jun 25, 2025 | Form 4 |
| Alan ListChief Medical Officer | 4,488 | – | May 2, 2024 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.04%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
- DFACDimensional U.S. Core Equity 2 ETFWeight in the fund0.00%
8 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 56
- Q4 2025: Managers 69
- Q1 2026: Managers 79
- Q2 2026: Managers 95
Institutional investors by quarter
The fund managers holding DTIL, quarter by quarter, from Q1 2019 to Q2 2025, 26 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 95 managers held 17.68M shares, worth $139M. During the quarter 30 opened a position, 15 closed one, 30 added and 14 trimmed.
The largest holders, Q2 2026
- Aberdeen GroupIn the quarter
- BleichroederIn the quarter+21%
- Octagon Capital AdvisorsIn the quarter-40%
- Boothbay Fund ManagementIn the quarter+26%
- BlackRockIn the quarter+487%
- Vanguard Capital ManagementIn the quarter+23%
- Lynx1 Capital ManagementIn the quarter-3.5%
- Driehaus Capital ManagementIn the quarter-4.9%
- Empery Asset ManagementIn the quarter-61%
- Affinity Asset AdvisorsIn the quarter+8.1%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Aberdeen Group | 2.23M | $18M | |
| Bleichroeder | 2.02M | +21% | $16M |
| Octagon Capital Advisors | 1.35M | -40% | $11M |
| Boothbay Fund Management | 1.35M | +26% | $11M |
| BlackRock | 1.17M | +487% | $9.2M |
| Vanguard Capital Management | 1.12M | +23% | $8.8M |
| Lynx1 Capital Management | 950.5K | -3.5% | $7.5M |
| Driehaus Capital Management | 946.7K | -4.9% | $7.4M |
| Empery Asset Management | 776.1K | -61% | $6.1M |
| Affinity Asset Advisors | 646.6K | +8.1% | $5.1M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Precision BioSciences's filings show?
Who buys and sells is one part of Precision BioSciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have DTIL's insiders bought or sold?
From Jun 3, 2026 to Nov 12, 2026 Precision BioSciences's insiders bought $29.5K and sold $27.5K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold DTIL?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $500.0K.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.